1231930-26-9

Basic information

• Product Name: 5-bromo-N-cyclopentyl-2-nitrobenzenamine
• Synonyms: 5-bromo-N-cyclopentyl-2-nitrobenzenamine
• CAS NO: 1231930-26-9
• Molecular Weight: 285.14
• Mol File: 1231930-26-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 5-bromo-N-cyclopentyl-2-nitrobenzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-N-cyclopentyl-2-nitrobenzenamine(1231930-26-9)
• EPA Substance Registry System: 5-bromo-N-cyclopentyl-2-nitrobenzenamine(1231930-26-9)

Safety Data

• Hazardous Substances Data: 1231930-26-9(Hazardous Substances Data)

Upstream product

• 51686-78-3 2,4-dibromonitrobenzene 
• 1003-03-8 Cyclopentamine 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 152684-30-5 5-bromo-2-methoxy-3-nitropyridine 
• 884495-39-0 5-bromo-2-(methyloxy)-3-pyridinamine 
• 1086063-46-8 N-(5-bromo-2-methoxypyridine-3-yl)-2,4-difluorobenzene sulfonyl chloride 
• 1083326-73-1 N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 108-36-1 1,3-dibromobenzene 

Downstream Products

• 1231930-27-0 5-bromo-N¹-cyclopentylbenzene-1,2-diamine 
• 1416333-06-6 2-amino-5-(2-amino-1-cyclopentyl-1H-benzimidazol-6-yl)-N-phenyl-3-pyridinesulfonamide 

Relevant articles and documents

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed are kinase inhibitor compounds having the following structure: (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3,R4, R5, R6, N-Ar, X, Y, Z, and AA are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Substituted benzimidazole derivatives

The invention belongs to the field of pharmaceutical chemistry, particularly relates to substituted benzimidazole derivatives as well as a preparation method and pharmaceutical composition thereof and further relates to an application of the substituted b

BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS

Provided are compounds of Formulas I, II, III, IV, V, and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).